For the Quarter Ending June 2026
Etoricoxib Prices in North America
- In the USA, the Etoricoxib Price Index rose by 18.87% quarter-over-quarter, driven by freight increases.
- The average Etoricoxib price for the quarter was approximately USD 85,213.33/MT on a CFR Houston basis.
- Etoricoxib Spot Price softened in June as ample exports offset sharp container freight escalation pressure.
- Etoricoxib Price Forecast indicates stabilization in July as restocking supports modest upward adjustments by August.
- Etoricoxib Production Cost Trend remained elevated from rerouted sailings and war-risk insurance surcharges inflating logistics.
- Etoricoxib Demand Outlook stays subdued as FDA non-approval restricts commercial uptake, sustaining niche clinical procurement.
- Etoricoxib Price Index volatility reflected freight swings while abundant origin allocations allowed buyer concessions recently.
- Major origin plants remained operational, enabling exports and limiting scarcity despite higher transport costs.
Why did the price of Etoricoxib change in June 2026 in North America?
- Ample export availability from India and Europe outweighed freight inflation, applying downward pressure on Etoricoxib.
- Freight surged heavily, but small-lot shipment economics diluted per-kilogram impact, moderating final price increases materially.
- No origin outages and comfortable container slots improved buyer leverage, enabling seller concessions in June.
Etoricoxib Prices in APAC
- In China, the Etoricoxib Price Index rose by 18.9% quarter-over-quarter, reflecting tighter domestic output constraints.
- The average Etoricoxib price for the quarter was approximately USD 85,060/MT, per Shanghai FOB market.
- Etoricoxib Spot Price tightened as inventories fell to roughly two weeks of forward demand levels.
- Etoricoxib Price Forecast projects a modest rebound after June correction as buyers resume restocking into Q3.
- Etoricoxib Production Cost Trend remained elevated due to regulatory compliance and fluorinated intermediate purification expenses.
- Etoricoxib Demand Outlook remains firm as post-patent generic launches boost export enquiries and contract volumes.
- Etoricoxib Price Index eased in June; export enquiries softened, producers offered concessions, thereby retaining share.
- Port operations remained fluid, supporting outbound FOB shipments, while domestic operating rates normalized across Zhejiang
Why did the price of Etoricoxib change in June 2026 in APAC?
- In June, ample domestic output increased exportable inventories, reducing spot tightness and pressuring FOB offers.
- Regulatory compliance and fluorinated intermediate purification raised production costs, limiting price flexibility despite weaker demand.
- Port logistics were normal, but restocking reduced buying urgency, causing sellers to concede prices, maintaining volumes.
India
- In India, the Etoricoxib Price Index rose by 14.19% quarter-over-quarter, reflecting formulators' replenishment and exporting.
- Etoricoxib Spot Price eased in June as prior restocking left distributors with comfortable inventory positions.
Etoricoxib Prices in Europe
- In Germany, the Etoricoxib Price Index rose by 18.97% quarter-over-quarter, reflecting tighter imports and higher GMP costs.
- The average Etoricoxib price for the quarter was approximately USD 85200.00/MT, reflecting elevated landed-cost dynamics.
- Competitive Etoricoxib spot prices from India pressured German CFR quotes despite logistics and audit premiums.
- Export tightness and longer laboratory release cycles influenced the Etoricoxib Production Cost Trend among Indian suppliers.
- Wholesale replenishment for hospital tenders supported the Etoricoxib Demand Outlook, sustaining baseline consumption through the quarter.
- Forward curves and procurement patterns underpin the Etoricoxib Price Forecast, showing volatility into the summer months.
- Inventory accumulation at German wholesalers and parallel trade restrictions affected the Etoricoxib Price Index and regional availability.
- Operator capacity shifts toward ibuprofen reduced Etoricoxib allocations, supporting periodic CFR strength despite downstream margin compression.
Why did the price of Etoricoxib change in June 2026 in Europe?
- Tighter Indian export availability and Southern European capacity diversion tightened supply, elevating landed costs into Hamburg.
- Falling solvent feedstock costs and weakened Euro partially offset freight and audit-related price pressures during June.
- Demand was tempered by mid-June reimbursement reforms, and inventory-driven buying reduced immediate offtake, pressuring spot quotations.
For the Quarter Ending March 2026
Etoricoxib Prices in North America
- In the USA, the Etoricoxib Price Index rose by 3.61% quarter-over-quarter, reflecting higher freight and compliance.
- The average Etoricoxib price for the quarter was approximately USD 71686.67/MT, reflecting small-lot landed costs.
- Etoricoxib Spot Price strengthened in March as tight export allocations from India raised offer levels.
- Etoricoxib Price Forecast anticipates modest recovery late Q2, driven by selective restocking and procurement activity.
- Etoricoxib Production Cost Trend reflected rising freight and insurance, offsetting savings from lower container rates.
- Etoricoxib Demand Outlook remains niche and inelastic, dominated by clinical trials and compassionate-use procurement patterns.
- Etoricoxib Price Index volatility was amplified by constrained exports, customs testing delays, and wholesaler inventories.
- Asian and European producers operated normally; allocations and audit fees sustained higher CFR Houston offers.
Why did the price of Etoricoxib change in March 2026 in North America?
- Sharp increase in container freight and insurance elevated landed import costs for small-batch Etoricoxib consignments.
- Tight export allocation from Indian suppliers reduced prompt availability, pressuring buyers to accept higher offers.
- Stringent CGMP audit fees and customs testing absorbed freight savings, sustaining pressure on landed prices.
Etoricoxib Prices in APAC
- In China, the Etoricoxib Price Index rose by 3.71% quarter-over-quarter, reflecting constrained supply and steady exports.
- The average Etoricoxib price for the quarter was approximately USD 71540/MT, supported by firm export enquiries and steady domestic demand.
- Etoricoxib Spot Price tightened in March as environmental inspections reduced prompt availability across eastern Chinese fluorination lines.
- Etoricoxib Price Forecast indicates mild further gains into April, driven by restocking and constrained feedstock availability.
- Etoricoxib Production Cost Trend rose due to tighter 2,2,2-trifluoroethanol supply and stricter emissions compliance measures.
- Etoricoxib Demand Outlook remains positive as Indian, Brazilian,n and South African buyers advanced procurement ahead of tenders.
- Etoricoxib Price Index showed upward momentum supported by normal inventories and uninterrupted port operations in Shanghai.
- Producers kept reactors running without major outages, keeping export cadence steady despite tighter feedstock delivery schedules.
Why did the price of Etoricoxib change in March 2026 in APAC?
- Environmental inspections in Zhejiang and Jiangsu curtailed operating days, reducing prompt API availability and tightening exportable volumes.
- Tighter 2,2,2-trifluoroethanol feedstock availability raised variable production costs, pressuring sellers to lift FOB Shanghai offers.
- Accelerated overseas procurement from India, Brazil, and South Africa increased enquiries, absorbing reduced March allocations quickly.
Etoricoxib Prices in Europe
- In Germany, the Etoricoxib Price Index rose by 3.692% quarter-over-quarter, reflecting tighter imports and tendering.
- The average Etoricoxib price for the quarter was approximately USD 71616.67/MT, per consolidated quarterly statistics.
- Etoricoxib Spot Price tightened as GMP validations and shipping reroutes reduced cargo availability at Hamburg.
- Etoricoxib Price Forecast signals recovery in April as importers replenish stocks ahead of tender deadlines.
- Etoricoxib Production Cost Trend rose due to higher freight and insurance premiums amid geopolitical tensions.
- Etoricoxib Demand Outlook remains firm with hospital tenders and steady outpatient prescriptions sustaining distributor replenishment.
- Etoricoxib Price Index strength reflected low bonded warehouse cover and strong parallel-trade exports, reducing stocks.
- Major Indian and Southern European producers operated, but validations and testing constrained export-grade output shipments.
Why did the price of Etoricoxib change in March 2026 in Europe?
- Export-side GMP validations and shipping reroutes reduced inbound volumes, tightening supply, elevating landed CFR costs.
- Accelerated orders ahead of health-insurance tenders, plus parallel exports, depleted bonded inventories,s and tightened availability.
- Euro appreciation partly cushioned dollar-denominated quotes, yet higher insurance and freight pressured landed costs.
For the Quarter Ending December 2025
North America
- In the USA, the Etoricoxib Price Index rose by 1.59% quarter-over-quarter, reflecting reduced Chinese exports and freight pressures.
- The average Etoricoxib price for the quarter was approximately USD 69188.33/MT on a CFR Houston basis.
- Etoricoxib Spot Price firmed early quarter as USD weakening versus CNY and freight increases elevated landed import costs.
- Etoricoxib Price Forecast indicates modest declines into December due to inventory consolidation and softer trial-related offtake.
- Etoricoxib Production Cost Trend was eased by falling Asia-US freight rates, marginally reducing landed cost pressure.
- Etoricoxib Demand Outlook remains narrow, driven by academic trials and compassionate-use imports, limiting broad pharmaceutical uptake.
- Etoricoxib Price Index movements reflected balanced distributor inventories, steady exports from India, and selective buyer purchasing patterns.
- Major supplier operations remained routine with no maintenance-related shutdowns, supporting continuous parcel-sized shipments into Houston.
Why did the price of Etoricoxib change in December 2025 in North America?
- Easing freight rates lowered landed costs, directly reducing import offers for parcel-sized Etoricoxib consignments into the US.
- Soft trial-related offtake and subdued restocking constrained demand, allowing distributors to run higher inventories without urgent purchases.
- Stable foreign factory production and lack of domestic capacity kept supply ample, pressuring Etoricoxib Price Index downward modestly.
APAC
- In China, the Etoricoxib Price Index rose by 1.4% quarter-over-quarter, driven by seasonal export recovery.
- The average Etoricoxib price for the quarter was approximately USD 68983.33/MT, reflecting stable export demand.
- Etoricoxib Spot Price showed mild softness in December amid subdued overseas buying and destocking activity.
- Etoricoxib Price Forecast indicates modest recovery in early 2026 as buyers gradually replenish post-holiday inventories.
- Etoricoxib Production Cost Trend shows modest upward pressure from wastewater compliance and fluorinated intermediate costs.
- Etoricoxib Demand Outlook remains cautious as VBP tender timing encourages hospitals to delay spot purchases.
- Etoricoxib Price Index pressure stemmed from ample finished-goods inventories and muted export inquiries from India, Brazil.
- Major Zhejiang and Jiangsu plants operated near nameplate capacity, keeping flows, limiting Etoricoxib Price Index volatility.
Why did the price of Etoricoxib change in December 2025 in APAC?
- Reduced buyer urgency and VBP tender uncertainty led to subdued offtake from hospitals and overseas formulators.
- Higher wastewater compliance and fluorinated intermediate monitoring increased costs, pressuring margins but not restricting output.
- Efficient port logistics and freight prevented delays, while firmer CNY reduced overseas arbitrage and enthusiasm.
Europe
- In Germany, the Etoricoxib Price Index rose by 1.43% quarter-over-quarter, reflecting mild restocking and firmer offers.
- The average Etoricoxib price for the quarter was approximately USD 69066.67/MT, based on shipment-weighted data.
- Etoricoxib Spot Price movements remained subdued amid steady Indian exports and comfortable bonded warehouse inventories.
- Etoricoxib Price Forecast points to modest near-term softness, followed by selective restocking in January 2026.
- Etoricoxib Production Cost Trend saw limited pressure as freight and feedstock costs remained neutral overall.
- Etoricoxib Demand Outlook stays steady with balanced pharmaceutical offtake and conservative wholesaler purchasing patterns currently.
- Price Index volatility was low, reflecting balanced supply, disciplined buyers, and routine regulatory release timing.
- Inventory coverage at German bonded warehouses supported liquidity while Hamburg operations remained fully operational throughout.
Why did the price of Etoricoxib change in December 2025 in Europe?
- Steady Indian exports and ample distributor stocks reduced urgency, softening landed offers and keeping prices muted.
- Year-end buying cycles remained subdued as wholesalers drew down earlier purchases, limiting fresh procurement thereby.
- Stable freight costs and neutral currency movements reduced landed-cost pressure; regulatory release delays extended lead times.
For the Quarter Ending September 2025
North America
- In USA, the Etoricoxib Price Index fell by 15.27% quarter-over-quarter, driven by excess imports and weak demand.
- The average Etoricoxib price for the quarter was approximately USD 68105/MT, reflecting CFR Houston trade patterns.
- Etoricoxib Spot Price softened amid elevated inventories and aggressive Asian export offers pressuring domestic quotations.
- Etoricoxib Price Forecast indicates initial July declines then modest recovery as restocking gradually resumes later.
- Etoricoxib Production Cost Trend showed downward pressure from lower landed costs offset by freight variations.
- Etoricoxib Demand Outlook remains subdued with weak pharmaceutical procurement and cautious downstream manufacturing activity levels.
- Etoricoxib Price Index movement reflected high inventories, softer consumption, and exporter pricing dynamics pressuring offers.
- Etoricoxib Spot Price sensitivity increased due to tariff uncertainty, freight volatility, and shifting import competitiveness.
Why did the price of Etoricoxib change in September 2025 in North America?
- Excess supply from reduced Asian export prices and high inventories pressured prices and procurement activity.
- Declining demand from pharmaceutical formulators and cautious downstream restocking limited upward price momentum despite signals.
- Freight rate fluctuations and tariff uncertainty altered landed costs, influencing import decisions and price dynamics.
APAC
- In China, the Etoricoxib Price Index fell by 15.28% quarter-over-quarter, reflecting inventories and weak export demand.
- The average Etoricoxib price for the quarter was approximately USD 68000/MT based on export shipments.
- Etoricoxib Spot Price firmed as Etoricoxib Production Cost Trend reflected raw material and freight expenses.
- Etoricoxib Price Forecast for September indicated gains driven by domestic replenishment and steady factory rates.
- Etoricoxib Demand Outlook improved slightly with pharmaceutical offtake supporting volumes despite weak international purchase momentum.
- Etoricoxib Price Index pressure persisted from high inventories and subdued export inquiries, limiting seller pricing power.
- Resumed output after scheduled plant maintenance combined with aggressive stock clearance kept market selling activity soft.
- Higher freight rates and currency shifts eroded export competitiveness, reducing inbound orders and pressuring margins.
Why did the price of Etoricoxib change in September 2025 in APAC?
- Elevated inventories reduced buying urgency, prompting suppliers to cut offers to clear aged stock quickly.
- Weak overseas orders combined with higher freight and tariff uncertainty diminished export demand and price support.
- Input cost declines earlier relieved manufacturing costs, but resurgent raw material inflation partially offset downward pressures.
Europe
- In Germany, the Etoricoxib Price Index fell by 15.26% quarter-over-quarter, reflecting weak demand and inventory.
- The average Etoricoxib price for the quarter was approximately USD 68090.00/MT, reported by German importers.
- Etoricoxib Spot Price remained subdued amid Chinese export discounts and ample domestic inventories, limiting buyers.
- Etoricoxib Price Forecast indicates mild recovery in coming months driven by restocking and downstream demand.
- Etoricoxib Production Cost Trend eased slightly with lower Asian export offers and softer raw materials.
- Etoricoxib Demand Outlook remains weak as pharmaceutical buyers defer orders amid high inventories, limiting procurement.
- Inventory overhang and muted export demand pressured Etoricoxib Price Index, prompting competitive seller discounts persistently.
- Major suppliers operated near-normal output, sustaining availability while selective restocking provided upward pressure on prices.
Why did the price of Etoricoxib change in September 2025 in Europe?
- Excess inventory and aggressive Asian export discounts reduced landed costs, exerting downward pressure on prices.
- Freight rate fluctuations and currency moves eased import expenses but higher shipping costs constrained procurement.
- Weak pharmaceutical and healthcare demand, combined with supplier discounts, discouraged buying and supported price declines.
